APA (7th ed.) Citation

ZG, W., HJ, C., DJ, W., Z, J., YY, P., LY, L., . . . XC, P. (2025). Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): A phase 2 clinical trial. Nature communications, 16(1), 8918. https://doi.org/10.1038/s41467-025-63978-y

Chicago Style (17th ed.) Citation

ZG, Wei, et al. "Neoadjuvant Tislelizumab with Afatinib for Locally Advanced Head and Neck Squamous Cell Carcinoma (neoCHANCE-1): A Phase 2 Clinical Trial." Nature Communications 16, no. 1 (2025): 8918. https://doi.org/10.1038/s41467-025-63978-y.

MLA (9th ed.) Citation

ZG, Wei, et al. "Neoadjuvant Tislelizumab with Afatinib for Locally Advanced Head and Neck Squamous Cell Carcinoma (neoCHANCE-1): A Phase 2 Clinical Trial." Nature Communications, vol. 16, no. 1, 2025, p. 8918, https://doi.org/10.1038/s41467-025-63978-y.